Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Expression”

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06500052
What this trial is testing

BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

Who this might be right for
Esophageal CancerGastric CancerPancreatic Cancer+2 more
Sichuan Baili Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT05671822
What this trial is testing

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Who this might be right for
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 258
Testing effectiveness (Phase 2)Looking for participantsNCT05403242
What this trial is testing

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Who this might be right for
Advanced Gastroesophageal Adenocarcinoma
Chinese PLA General Hospital 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT06198751
What this trial is testing

Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 104
Not applicableLooking for participantsNCT06909604
What this trial is testing

Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy

Who this might be right for
Breast Cancer
Peking University Cancer Hospital & Institute 50
Not applicableUnknownNCT05834699
What this trial is testing

HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC

Who this might be right for
Breast Cancer
Beijing 302 Hospital 50
Not applicableStudy completedNCT05412459
What this trial is testing

99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy

Who this might be right for
HER2-positive Breast CancerFemale
Tomsk National Research Medical Center of the Russian Academy of Sciences 15
Testing effectiveness (Phase 2)UnknownNCT05113459
What this trial is testing

Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）

Who this might be right for
Gastric Cancer
Guoxin Li 40
Not applicableStudy completedNCT05217381
What this trial is testing

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Who this might be right for
Early Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
MedSIR 18,533
Testing effectiveness (Phase 2)Looking for participantsNCT07653685
What this trial is testing

A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.

Who this might be right for
Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 71
Testing effectiveness (Phase 2)Study completedNCT00479674
What this trial is testing

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Duke University 41
Testing effectiveness (Phase 2)UnknownNCT05749575
What this trial is testing

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Who this might be right for
Breast Cancer
Sun Yat-sen University 28
Large-scale testing (Phase 3)Looking for participantsNCT05904964
What this trial is testing

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Who this might be right for
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 288
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592625
What this trial is testing

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

Who this might be right for
Untreated Early-stage or Locally Advanced Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 60
Not applicableUnknownNCT06243432
What this trial is testing

Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer

Who this might be right for
Advanced Breast Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 600
Testing effectiveness (Phase 2)Active Not RecruitingNCT05824325
What this trial is testing

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

Who this might be right for
Breast Cancer
Fudan University 56
Not applicableUnknownNCT04365790
What this trial is testing

Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma

Who this might be right for
Breast Cancer
Hellenic Cooperative Oncology Group 500
Testing effectiveness (Phase 2)UnknownNCT05018676
What this trial is testing

ARX788 in Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer With Low Expression of HER2
Fudan University 54
Testing effectiveness (Phase 2)Looking for participantsNCT06131450
What this trial is testing

BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Who this might be right for
Gynecological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd. 138
Testing effectiveness (Phase 2)UnknownNCT06227156
What this trial is testing

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Castration-resistant Prostate Cancer
RemeGen Co., Ltd. 40
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation